Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Public offering nets $188mm for Natera

Executive Summary

Natera Inc. netted $188mm through a public offering of 5.7mm common shares at $35. The company is developing molecular diagnostics for reproductive health, oncology (treatment and recurrence monitoring and molecular residual disease testing), and transplant rejection assessment.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register